Institutional and Insider Ownership
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Bio-Path has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Valuation and Earnings
This table compares Bio-Path and Silverback Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Path | N/A | N/A | -$16.08 million | ($1.82) | -0.05 |
| Silverback Therapeutics | N/A | N/A | -$89.48 million | ($2.42) | -3.70 |
Silverback Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Bio-Path and Silverback Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Path | N/A | -2,842.40% | -337.48% |
| Silverback Therapeutics | N/A | -29.62% | -28.20% |
Summary
Silverback Therapeutics beats Bio-Path on 5 of the 8 factors compared between the two stocks.
About Bio-Path
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
About Silverback Therapeutics
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
